Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Blood (2024) 144 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2024-193827

Published: 2024

Journal Articles

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Blood (2023) 142 (Supplement 1): 897.

https://doi.org/10.1182/blood-2023-187859

Published: 2023

Journal Articles

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Blood (2023) 142 (Supplement 1): 475.

https://doi.org/10.1182/blood-2023-188032

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Blood (2022) 140 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2022-171463

Published: 2022

Journal Articles

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Blood (2021) 138 (Supplement 1): 2955.

https://doi.org/10.1182/blood-2021-149313

Published: 2021

Journal Articles

A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-143079

Published: 2020

Journal Articles

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Emily Harris, Ariel Sindel, DO, Ian McConnell, William Clark, MDMS, Alden Chesney, MD, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5266.

https://doi.org/10.1182/blood-2019-130921

Published: 2019

Journal Articles

Absence of Viral Complications When Using Rituximab to Treat TTP with Plasma Exchange

Gail Rock, PhD MD, Steven Weger, MD, Hana Abouhadjar, MD, David Barth, MD FRCPC, William Clark, MD, Paul R. Yenson, MD FRCPC, Stephen Ronan Foley, MD FRCPC

Blood (2015) 126 (23): 2261.

https://doi.org/10.1182/blood.V126.23.2261.2261

Published: 2015

Journal Articles

Dual Inhibition of MDM2 and BET Cooperate to Eradicate Acute Myeloid Leukemia

Anne-Louise Latif, MBChB, John J Cole, Joana Monteiro Campos, William Clark, Lynn McGarry, PhD, Claire Brock, Ashley Newcombe, Karen Keeshan, PhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Peter D Adams, PhD

Blood (2015) 126 (23): 674.

https://doi.org/10.1182/blood.V126.23.674.674

Published: 2015

Journal Articles

Favorable Outcomes in Patients with High Donor-Derived T Cell Count Following In Vivo T Cell Depleted Reduced Intensity Allogeneic Stem Cell Transplantation

Amir A Toor, MD, Roy T Sabo, PhD, Harold M Chung, MD, Catherine H Roberts, PhD, Rose H Manjili, BS, Shiyu Song, MD, PhD, David C. Williams, Jr., MD, PhD, William Clark, MD, Masoud H Manjili, DVM, PhD, John M McCarty, MD

Blood (2011) 118 (21): 3043.

https://doi.org/10.1182/blood.V118.21.3043.3043

Published: 2011

Journal Articles

Adaptive Immunotherapy In Multiple Myeloma: Epigenetic Modification and Immunomodulation by Sequential Azacitidine and Lenalidomide to Generate Cancer Testis Antigen Specific Cellular Immune Response

Amir A Toor, MD, Kyle Payne, BS, Harold M Chung, MD, Catherine H Roberts, PhD, Roy T Sabo, PhD, Maciej Kmieciak, PhD, William Clark, MD, Christy McLaughlin, BS, Angela Buskey, RN, Jennifer Anderson, RN, Rose H Manjili, BS, Susan D. Roseff, MD, John M McCarty, MD, Masoud H Manjili, DVM, PhD

Blood (2011) 118 (21): 2926.

https://doi.org/10.1182/blood.V118.21.2926.2926

Published: 2011

Journal Articles

Genetic Variation In Recipient BAFF Modulates Phenotype of Chronic GvHD After HCT

William Clark, MD, Dana Crawford, Ph.D, Brian Engelhardt, MD, MS, Kristin D. Brown, Fan Kang-Hsien, PhD, Heidi Chen, PhD, Bipin N. Savani, MD, Friedrich Schuening, MD, John P. Greer, MD, Adetola A. Kassim, MD, MS, Madan Jagasia, MD, MS

Blood (2010) 116 (21): 215.

https://doi.org/10.1182/blood.V116.21.215.215

Published: 2010

Journal Articles

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Blood (2008) 112 (11): 2293.

https://doi.org/10.1182/blood.V112.11.2293.2293

Published: 2008

Journal Articles

ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma.

Gail A. Rock, Phd, MD, FRCPC, David Anderson, MD, Barrett Benny, MD, David Barth, MD, William Clark, MD, Ronan Foley, MD, David Sutton, MD, Pierre Leblond, MD

Blood (2007) 110 (11): 2895.

https://doi.org/10.1182/blood.V110.11.2895.2895

Published: 2007

Journal Articles

Treatment of Thrombotic Thrombocytopenic Purpura Using Solvent Detergent Treated Plasma.

Gail Rock, PhD, MD, FRCP, David Anderson, Barrett Benny, William Clark, Pierre Leblond, David Sutton, Marion Sternbach, George Wells, Members of the Canadian Apheresis Group, Canadian Association of Apheresis Nurses

Blood (2005) 106 (11): 3989.

https://doi.org/10.1182/blood.V106.11.3989.3989

Published: 2005

Journal Articles

Hemolytic Uremic Syndrome Is an Immune Mediated Disease: Role of Anti-CD36 Antibodies.

Gail Rock, PhD, MD, William Clark, Marion Sternbach, Maria Kolajova, Peter McLaine

Blood (2005) 106 (11): 3990.

https://doi.org/10.1182/blood.V106.11.3990.3990

Published: 2005

Journal Articles

STANDARDIZATION OF THE QUICK PROTHROMBIN TEST : WITH REFERENCE TO THE STATISTICAL SIGNIFICANCE OF VARIATIONS IN THE PROTHROMBIN CONCENTRATION WITH USE OF A STABLE THROMBOPLASTIN OF HIGH POTENCY

PAUL M. AGGELER, M.D., JOAN HOWARD, A.B., S. P. LUCIA, M.D., WILLIAM CLARK, A.B., ALEXIS ASTAFF, D.D.S.

Blood (1946) 1 (3): 220–233.

https://doi.org/10.1182/blood.V1.3.220.220

Published: 1946

NARROW

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation

Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Transformation from Indolent Primary Cutaneous Marginal Zone Lymphoma to Aggressive Primary Cutaneous Diffuse Large B-Cell Lymphoma: A Rare Case and Review of the Literature

Absence of Viral Complications When Using Rituximab to Treat TTP with Plasma Exchange

Dual Inhibition of MDM2 and BET Cooperate to Eradicate Acute Myeloid Leukemia

Favorable Outcomes in Patients with High Donor-Derived T Cell Count Following In Vivo T Cell Depleted Reduced Intensity Allogeneic Stem Cell Transplantation

Adaptive Immunotherapy In Multiple Myeloma: Epigenetic Modification and Immunomodulation by Sequential Azacitidine and Lenalidomide to Generate Cancer Testis Antigen Specific Cellular Immune Response

Genetic Variation In Recipient BAFF Modulates Phenotype of Chronic GvHD After HCT

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma.

Treatment of Thrombotic Thrombocytopenic Purpura Using Solvent Detergent Treated Plasma.

Hemolytic Uremic Syndrome Is an Immune Mediated Disease: Role of Anti-CD36 Antibodies.

STANDARDIZATION OF THE QUICK PROTHROMBIN TEST : WITH REFERENCE TO THE STATISTICAL SIGNIFICANCE OF VARIATIONS IN THE PROTHROMBIN CONCENTRATION WITH USE OF A STABLE THROMBOPLASTIN OF HIGH POTENCY

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only